Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol)
Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol) FDA approval of…
Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol) FDA approval of…
Tel Aviv, Israel, Sep 21, 2022 – (ACN Newswire) – Spool, the DAO creating a…
Underwriter Assistant automates onerous admin tasks, freeing underwriters to underwrite LAS VEGAS–(BUSINESS WIRE)–Eigen Technologies (Eigen),…
On the heels of a ship strike killing Fran, the most photographed whale in California,…
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA releases its auto loan ABS indices for August 2022, providing monthly credit…
FF’s flagship FF 91 Futurist EV has received an official EPA rating of 381 miles…
NEW YORK–(BUSINESS WIRE)–#americanexpress–SmartMetric, Inc. (OTCQB: SMME): Goode Intelligence, a London based research company has listed…
Global Distributor Offers Newest Technologies Available Today DALLAS & FORT WORTH, Texas–(BUSINESS WIRE)–#electronics—Mouser Electronics, Inc.,…
NEW YORK–(BUSINESS WIRE)–Deutsche Bank announced today its appointment as depositary bank for the Global Depositary…
DUBLIN–(BUSINESS WIRE)–The “Active Pharmaceutical Ingredients Market Analysis by Type of Synthesis, by Type of Manufacturers,…
Cost Per Installation (CPI) has steadily declined since June 2021, despite inflation Fintech users activate…
DUBLIN–(BUSINESS WIRE)–The “Traffic Sensor Market Research Report by Type (Bending Plate Sensor, Image Sensor, and…
Collaboration enriches NVIDIA DRIVE Sim’s library of vehicle, sensor and traffic models for accurate testing…
Enhanced functionalities round out Xerox’s Capture & Content Services NORWALK, Conn.–(BUSINESS WIRE)–Today, Xerox announced a…
Utah-Based Startup Provides Insights to Over 180 Tourism Organizations SALT LAKE CITY–(BUSINESS WIRE)–Zartico, a company…
DUBLIN–(BUSINESS WIRE)–The “Cloud Identity & Access Management Market Research Report by Solution, Industry, Deployment, Region…
Clinical assessments three-months post-treatment report no serious adverse events and reduced seizure frequency to date…
2022 half-year results Slight business growth H1 revenue: €371.1 million, up 2.2% (-1.3% at CER1); sustained…
New clinical data from phase I trial UV1-103, combining UV1 with pembrolizumab in advanced melanoma…
Live video webcast fireside chat on Thursday, September 29th at 11:30 AM ET CARLSBAD, Calif.,…